The AMA and ACOG have collaborated to revise billing codes for maternity care service, which will better reflect modern obstetric practice.

Drug companies involved in price deals with President Trump have continued to raise prices on hundreds of medications.

High-dose tirzepatide is associated with superior HbA1c reduction and weight loss compared with semaglutide in type 2 ...

Tirzepatide significantly improves health-related quality of life and physical functioning compared with dulaglutide in ...

Phase 3 trial data show a synthetic semaglutide injection provides glycemic control comparable to Ozempic in patients with ...

Veligrotug yields rapid and substantial reductions in proptosis for adults with active thyroid eye disease, according to ...

Orforglipron significantly reduces body weight across all BMI categories in the ATTAIN-1 trial, with results presented at ...

Teplizumab is now approved for children as young as 1 year with stage 2 type 1 diabetes, following study results on safety and pharmacokinetics.

Once-weekly lonapegsomatropin shows sustained safety and efficacy up to 90 weeks in adults with GHD, according to AACE 2026 ...

Crinecerfont allows for significant glucocorticoid dose reductions in adults with classic CAH while maintaining androgen control.

Patients with hematologic malignancies have an increased risk for cardiovascular disease (CVD) compared with the general population.

The FDA will soon review whether certain peptides should be allowed in customized medications made by compounding pharmacies.